Valerio L, Matrone A
Explor Target Antitumor Ther. 2025; 6:1002291.
PMID: 40061140
PMC: 11886382.
DOI: 10.37349/etat.2025.1002291.
Yang R, Yao J, Ma H, Shui C, Li T, Zhang S
Thyroid Res. 2025; 18(1):9.
PMID: 40001245
PMC: 11863774.
DOI: 10.1186/s13044-024-00222-7.
Benson P, Abdel-Rahman O
Immunotherapy. 2025; 17(1):47-55.
PMID: 39895320
PMC: 11834419.
DOI: 10.1080/1750743X.2025.2455922.
Fan S, Yuan Y, Su Y, Sang D
SAGE Open Med Case Rep. 2025; 13:2050313X241313084.
PMID: 39877673
PMC: 11773542.
DOI: 10.1177/2050313X241313084.
Cendra A, Pekarek L, Pedrejon B, Bernier L, Cervantes E, Cendra C
J Cancer. 2025; 16(1):241-264.
PMID: 39744583
PMC: 11660124.
DOI: 10.7150/jca.101395.
Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021.
Meng Z, Pan T, Yu J, Shi C, Liu X, Xue D
Front Endocrinol (Lausanne). 2024; 15:1500926.
PMID: 39713055
PMC: 11658972.
DOI: 10.3389/fendo.2024.1500926.
Nearly Half of Patients with Anaplastic Thyroid Cancer May Be Amenable to Immunotherapy.
Chern B, Pinto D, Lum J, Parameswaran R
Biomedicines. 2024; 12(6).
PMID: 38927511
PMC: 11201491.
DOI: 10.3390/biomedicines12061304.
SETMAR Facilitates the Differentiation of Thyroid Cancer by Regulating SMARCA2-Mediated Chromatin Remodeling.
Zhang W, Ruan X, Huang Y, Zhang W, Xu G, Zhao J
Adv Sci (Weinh). 2024; 11(32):e2401712.
PMID: 38900084
PMC: 11348079.
DOI: 10.1002/advs.202401712.
Ferroptosis and circular RNAs: new horizons in cancer therapy.
Bhat A, Kukreti N, Afzal M, Goyal A, Thapa R, Ali H
EXCLI J. 2024; 23:570-599.
PMID: 38887390
PMC: 11180955.
DOI: 10.17179/excli2024-7005.
Trends and projections of the global burden of thyroid cancer from 1990 to 2030.
Hu S, Wu X, Jiang H
J Glob Health. 2024; 14:04084.
PMID: 38751316
PMC: 11109522.
DOI: 10.7189/jogh.14.04084.
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.
Rodrigues J, Chenlo M, Bravo S, Perez-Romero S, Suarez-Farina M, Sobrino T
Nat Commun. 2024; 15(1):3736.
PMID: 38744818
PMC: 11094195.
DOI: 10.1038/s41467-024-47751-1.
Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
Priantti J, Rodrigues N, de Moraes F, Costa A, Jezini D, Heckmann M
Endocrine. 2024; 86(1):284-292.
PMID: 38709445
DOI: 10.1007/s12020-024-03845-w.
A prediction model based on random survival forest analysis of the overall survival of elderly female papillary thyroid carcinoma patients: a SEER-based study.
Lun Y, Yuan H, Ma P, Chen J, Lu P, Wang W
Endocrine. 2024; 85(3):1252-1260.
PMID: 38558373
DOI: 10.1007/s12020-024-03797-1.
Knowledge mapping of anaplastic thyroid cancer treatments: a bibliometric analysis (2000-2023).
Liu S, Yan X, Yang Y, Xia Y, Zhang P
Front Oncol. 2024; 14:1330030.
PMID: 38420016
PMC: 10899696.
DOI: 10.3389/fonc.2024.1330030.
Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials.
Wang K, Zhang Y, Xing Y, Wang H, He M, Guo R
Discov Oncol. 2024; 15(1):50.
PMID: 38403820
PMC: 10894806.
DOI: 10.1007/s12672-024-00904-6.
Response to sorafenib in a locally advanced oncocytic cell carcinoma of the thyroid.
Pereira A, Parra D, Alvarez M, Rincon O
BMJ Case Rep. 2024; 17(2).
PMID: 38378588
PMC: 10882407.
DOI: 10.1136/bcr-2023-257738.
Correlation analysis of serum thyroglobulin, thyroid-stimulating hormone levels, and thyroid-cancer risk in thyroid nodule surgery.
Shuai J, Leng Z, Wang P, Ji Y
World J Clin Cases. 2023; 11(27):6407-6414.
PMID: 37900235
PMC: 10600984.
DOI: 10.12998/wjcc.v11.i27.6407.
Co-inhibition of glutaminolysis and one-carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer.
Hwang Y, Yun H, Jeong J, Kim M, Joo S, Lee H
Cell Death Dis. 2023; 14(8):515.
PMID: 37573361
PMC: 10423221.
DOI: 10.1038/s41419-023-06041-2.
Update on Molecular Diagnostics in Thyroid Pathology: A Review.
Alzumaili B, Sadow P
Genes (Basel). 2023; 14(7).
PMID: 37510219
PMC: 10379610.
DOI: 10.3390/genes14071314.
Disparities in Presentation, Treatment, and Survival in Anaplastic Thyroid Cancer.
Ginzberg S, Gasior J, Passman J, Soegaard Ballester J, Finn C, Karakousis G
Ann Surg Oncol. 2023; 30(11):6788-6798.
PMID: 37474696
DOI: 10.1245/s10434-023-13945-y.